A. A. Sandberg and J. A. Bridge, Updates on the cytogenetics and molecular genetics 832 of bone and soft tissue tumors, Mesothelioma. Cancer Genet Cytogenet, vol.127, issue.2, pp.93-110, 2001.

M. Musti, E. Kettunen, and S. Dragonieri, Cytogenetic and molecular genetic 834 changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, issue.1, pp.9-15, 2006.

Y. Sekido, Genomic abnormalities and signal transduction dysregulation in 836 malignant mesothelioma cells, Cancer Sci, vol.101, issue.1, pp.1-6, 2010.

Z. Gibas, F. P. Li, K. H. Antman, S. Bernal, R. Stahel et al., Chromosome 838 changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.20, issue.3-4, pp.191-201, 1986.

A. Hagemeijer, M. A. Versnel, and E. Van-drunen, Cytogenetic analysis of 840 malignant mesothelioma, Cancer Genet Cytogenet, vol.47, issue.1, pp.1-28, 1990.

M. Krismann, K. M. Muller, M. Jaworska, and G. Johnen, Molecular cytogenetic 842 differences between histological subtypes of malignant mesotheliomas: DNA cytometry and 843 comparative genomic hybridization of 90 cases, J Pathol, vol.197, issue.3, pp.363-371, 2002.

P. M. Lindholm, K. Salmenkivi, and H. Vauhkonen, Gene copy number analysis 845 in malignant pleural mesothelioma using oligonucleotide array CGH, Cytogenet Genome Res, vol.846, issue.1-2, pp.46-52, 2007.

T. Taniguchi, S. Karnan, and T. Fukui, Genomic profiling of malignant pleural 848 mesothelioma with array-based comparative genomic hybridization shows frequent non-849 random chromosomal alteration regions including JUN amplification on 1p32, Cancer Sci, vol.850, issue.3, pp.438-446, 2007.

S. V. Ivanov, J. Miller, and R. Lucito, Genomic events associated with

M. Cheung, P. J. Pei, Y. Jhanwar, S. C. Pass, H. I. Testa et al., The promyelocytic 854 leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma 855 cells and contributes to cell survival, Oncogene, vol.29, issue.11, pp.1633-1640, 2010.

B. C. Christensen, E. A. Houseman, and G. M. Poage, Integrated profiling reveals a 857 global correlation between epigenetic and genetic alterations in mesothelioma, Cancer Res, vol.858, issue.14, pp.5686-5694, 2010.

D. Jean, E. Thomas, and M. E. , Syntenic Relationships between Genomic 860 Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.861, issue.2, pp.881-894, 2011.

R. Bueno, A. De-rienzo, and L. Dong, Second generation sequencing of the 863 mesothelioma tumor genome, PLoS One, vol.5, issue.5, p.10612, 2010.

J. F. Lechner, T. Tokiwa, and M. Laveck, Asbestos-associated chromosomal 865 changes in human mesothelial cells, Proc Natl Acad Sci U S A, vol.82, issue.11, pp.3884-3888, 1985.

M. C. Jaurand, A. Renier, J. Daubriac, and . Mesothelioma, Do asbestos and carbon 867 nanotubes pose the same health risk?, Part Fibre Toxicol, vol.6, p.16, 2009.

M. Tiainen, L. Tammilehto, J. Rautonen, T. Tuomi, K. Mattson et al.,

, Chromosomal abnormalities and their correlations with asbestos exposure and survival in 870 patients with mesothelioma, Br J Cancer, vol.60, issue.4, pp.618-626, 1989.

L. Tammilehto, T. Tuomi, and M. Tiainen, Malignant mesothelioma: clinical 872 characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients, Eur J 873 Cancer, vol.28, issue.8-9, pp.1373-1379, 1992.

P. B. Illei, M. Ladanyi, V. W. Rusch, and M. F. Zakowski, The use of CDKN2A deletion 875 as a diagnostic marker for malignant mesothelioma in body cavity effusions, Cancer, vol.876, issue.1, pp.51-56, 2003.

M. Takeda, T. Kasai, and Y. Enomoto, 9p21 deletion in the diagnosis of 996 malignant mesothelioma, using fluorescence in situ hybridization analysis, Pathol Int, vol.997, issue.5, pp.395-399, 2010.

J. Q. Cheng, S. C. Jhanwar, and W. M. Klein, p16 alterations and deletion mapping 999 of 9p21-p22 in malignant mesothelioma, Cancer Res, vol.54, issue.21, pp.5547-5551, 1994.

R. A. Kratzke, G. Otterson, and C. E. Lincoln, Immunohistochemical analysis of 1001 the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma, J Natl Cancer, p.1002

. Inst, , vol.87, pp.1870-1875, 1995.

M. Ladanyi, Implications of P16/CDKN2A deletion in pleural mesotheliomas

, Lung Cancer, vol.49, issue.1, pp.95-98, 2005.

S. Dacic, H. Kothmaier, and S. Land, Prognostic significance of p16/cdkn2a loss 1006 in pleural malignant mesotheliomas, Virchows Arch, vol.453, issue.6, pp.627-635, 2008.

K. Shigemitsu, Y. Sekido, and N. Usami, Genetic alteration of the beta-catenin

, gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a 1009 new 3p21.3 homozygous deletion, Oncogene, vol.20, issue.31, pp.4249-4257, 2001.

K. Uematsu, S. Kanazawa, and L. You, Wnt pathway activation in 1011 mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-1012 catenin, Cancer Res, vol.63, issue.15, pp.4547-4551, 2003.

S. G. Gray, D. A. Fennell, L. Mutti, O. Byrne, and K. J. , In arrayed ranks: array technology 1014 in the study of mesothelioma, J Thorac Oncol, vol.4, issue.3, pp.411-425, 2009.

E. Kettunen, A. M. Nissen, and T. Ollikainen, Gene expression profiling of 1016 malignant mesothelioma cell lines : cDNA array study, Int J Cancer, vol.91, issue.4, pp.492-496, 2001.

S. Mohr, G. Keith, F. Galateau-salle, P. Icard, and B. H. Rihn, Cell protection, 1018 resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray

S. Mohr, M. C. Bottin, and B. Lannes, Microdissection, mRNA amplification and 1021 microarray: a study of pleural mesothelial and malignant mesothelioma cells, Biochimie, vol.1022, issue.1, pp.13-19, 2004.

E. Kettunen, A. G. Nicholson, and B. Nagy, Identification of novel candidate 1027 oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale 1028 transcriptional profiling, Carcinogenesis, vol.10, issue.1, pp.1827-1840, 1026.

S. Singhal, R. Wiewrodt, and L. D. Malden, Gene expression profiling of 1030 malignant mesothelioma, Clin Cancer Res, vol.9, issue.8, pp.3080-3097, 2003.

S. Crispi, R. A. Calogero, and M. Santini, Global gene expression profiling of 1032 human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as 1033 potential tumour target, Am J Pathol, vol.4, issue.9, pp.762-770, 1036.

A. V. Ivanova, S. V. Ivanov, and L. Prudkin, Mechanisms of FUS1/TUSC2 1038 deficiency in mesothelioma and its tumorigenic transcriptional effects, Mol Cancer, vol.1039, p.80, 2009.

C. D. Hoang, D. 'cunha, J. Kratzke, and M. G. , Gene expression profiling identifies 1041 matriptase overexpression in malignant mesothelioma, J Natl Cancer Inst, vol.125, issue.5, pp.598-605, 2003.

G. J. Gordon, G. N. Rockwell, and P. A. Godfrey, Four-gene expression ratio test for 1048 survival in patients undergoing surgery for mesothelioma, J Natl Cancer Inst, vol.11, issue.12, pp.678-686, 1047.

G. V. Glinsky, O. Berezovska, and A. B. Glinskii, Microarray analysis identifies a 1051 death-from-cancer signature predicting therapy failure in patients with multiple types of 1052 cancer, J Clin Invest, vol.115, issue.6, pp.1503-1521, 2005.

S. Crispi, C. Fagliarone, and A. Biroccio, Protumorigenic role of HAPLN1 1056 and its IgV domain in malignant pleural mesothelioma, Clin Cancer Res, vol.70, issue.3, p.87, 1055.

X. Yang, X. Sun, O. D. Roe, E. Anderssen, H. Sandeck et al., Meta-analysis of several gene lists for distinct types of cancer: 1059 A simple way to reveal common prognostic markers, BMC Bioinformatics, vol.8, issue.1, 2007.

, Malignant pleural mesothelioma: genome-wide expression patterns reflecting general 1062 resistance mechanisms and a proposal of novel targets, Lung Cancer, vol.67, issue.1, pp.57-68, 2010.

M. A. Lemmon and J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell, vol.141, issue.7, pp.1117-1134, 1064.

J. G. Edwards, D. E. Swinson, J. L. Jones, D. A. Waller, O. Byrne et al., EGFR 1066 expression: associations with outcome and clinicopathological variables in malignant pleural 1067 mesothelioma, Lung Cancer, vol.54, issue.3, pp.399-407, 2006.

H. Kothmaier, F. Quehenberger, and I. Halbwedl, EGFR and PDGFR 1069 differentially promote growth in malignant epithelioid mesothelioma of short and long term 1070 survivors, Thorax, vol.63, issue.4, pp.345-351, 2008.

A. Destro, G. L. Ceresoli, and M. Falleni, EGFR overexpression in malignant 1072 pleural mesothelioma. An immunohistochemical and molecular study with clinico-1073 pathological correlations, Lung Cancer, vol.51, issue.2, pp.207-215, 2006.

V. Agarwal, M. J. Lind, L. Cawkwell, R. Govindan, R. A. Kratzke et al., Targeted epidermal growth factor receptor 1075 therapy in malignant pleural mesothelioma: Where do we stand? Cancer Treat Rev, Clin Cancer, vol.94, p.1078, 1076.

, Res, vol.11, issue.6, pp.2300-2304, 2005.

D. M. Jackman, H. L. Kindler, and B. Y. Yeap, Phase II study of erlotinib in patients 1083 with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, vol.113, issue.4, pp.2406-2413, 2007.

K. J. Butnor, J. L. Burchette, T. A. Sporn, S. P. Hammar, and V. L. Roggli, The spectrum of

, Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-1087 source antibody with a review of the literature, Arch Pathol Lab Med, vol.128, issue.5, pp.538-543, 2004.

A. E. Horvai, L. Li, Z. Xu, M. J. Kramer, D. M. Jablons et al., c-Kit is not 1089 expressed in malignant mesothelioma, Mod Pathol, vol.16, issue.8, pp.818-822, 2003.

A. Y. Lee, D. J. Raz, B. He, and D. M. Jablons, Update on the molecular biology of 1091 malignant mesothelioma, Cancer, vol.109, issue.8, pp.1454-1461, 2007.

S. Kumar-singh, J. Weyler, M. J. Martin, P. B. Vermeulen, and E. Van-marck,

, Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta 1094 expression, J Pathol, vol.189, issue.1, pp.72-78, 1999.

K. Aoe, A. Hiraki, and T. Tanaka, Expression of vascular endothelial growth 1096 factor in malignant mesothelioma, Anticancer Res, vol.26, issue.6C, pp.4833-4836, 2006.

F. Demirag, E. Unsal, A. Yilmaz, and A. Caglar, Prognostic significance of vascular 1098 endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural 1099 mesothelioma, Chest, vol.128, issue.5, pp.3382-3387, 2005.

Y. Ohta, V. Shridhar, and R. K. Bright, VEGF and VEGF type C play an 1101 important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma 1102 tumours, Br J Cancer, vol.81, issue.1, pp.54-61, 1999.

J. Konig, E. Tolnay, T. Wiethege, and K. Muller, Co-expression of vascular 1104 endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma

, Respiration, vol.67, issue.1, pp.36-40, 2000.

L. Strizzi, A. Catalano, and G. Vianale, Vascular endothelial growth factor is an 1107 autocrine growth factor in human malignant mesothelioma, J Pathol, vol.193, issue.4, pp.468-475, 2001.

A. L. Filho, F. Baltazar, C. Bedrossian, C. Michael, and F. C. Schmitt,

, Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma

, Diagn Cytopathol, vol.35, issue.12, pp.786-791, 2007.

R. Masood, A. Kundra, and S. Zhu, Malignant mesothelioma growth inhibition 1112 by agents that target the VEGF and VEGF-C autocrine loops, Int J Cancer, vol.104, issue.5, p.610, 2003.

M. Romano, A. Catalano, and M. Nutini, 5-lipoxygenase regulates malignant 1115 mesothelial cell survival: involvement of vascular endothelial growth factor, FASEB J. Page, vol.49

G. Pasello and A. Favaretto, Molecular targets in malignant pleural mesothelioma 1118 treatment, Curr Drug Targets, vol.10, issue.12, pp.1235-1244, 2009.

B. I. Gerwin, J. F. Lechner, and R. R. Reddel, Comparison of production of 1120 transforming growth factor-beta and platelet-derived growth factor by normal human 1121 mesothelial cells and mesothelioma cell lines, Cancer Res, vol.47, issue.23, pp.6180-6184, 1987.

M. A. Versnel, L. Claesson-welsh, and A. Hammacher, Human malignant 1123 mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial 1124 cells express predominantly PDGF alpha-receptors, Oncogene, vol.6, issue.11, pp.2005-2011, 1991.

M. Ramael, C. Buysse, J. Van-den-bossche, K. Segers, and E. Van-marck,

, Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in 1127 malignant mesothelioma and non-neoplastic mesothelium, J Pathol, vol.167, issue.1, pp.1-4, 1992.

J. Zhong, M. M. Gencay, and L. Bubendorf, ERK1/2 and p38 MAP kinase 1129 control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison 1130 between mesothelioma and mesothelial cells, J Cell Physiol, vol.207, issue.2, pp.540-552, 2006.

L. Fredriksson, H. Li, and U. Eriksson, The PDGF family: four gene products form 1132 five dimeric isoforms, Cytokine Growth Factor Rev, vol.15, issue.4, pp.197-204, 2004.

P. Heldin, T. Asplund, D. Ytterberg, S. Thelin, and T. C. Laurent, Characterization of 1134 the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-1135 derived growth factor in human mesothelial cells, Biochem J, vol.283, pp.165-170, 1992.

A. Jacobson, J. Brinck, M. J. Briskin, A. P. Spicer, and P. Heldin, Expression of human 1137 hyaluronan synthases in response to external stimuli, Biochem J, vol.348, pp.29-35, 2000.

A. Der-meeren, M. B. Seddon, C. A. Betsholtz, J. F. Lechner, and B. I. Gerwin,

, Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived 1140 growth factor-A chain overexpression, Am J Respir Cell Mol Biol, vol.8, issue.2, pp.214-221, 1993.

L. J. Metheny-barlow, F. B. Van-gijssel, H. E. Marrogi, A. Gerwin, and B. I. ,

, Paradoxical effects of platelet-derived growth factor-A overexpression in malignant 1143 mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo, Am J, p.1144

, Respir Cell Mol Biol, vol.24, issue.6, pp.694-702, 2001.

A. Mathy, P. Baas, O. Dalesio, and N. Van-zandwijk, Limited efficacy of imatinib 1146 mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, issue.1, pp.83-86, 2005.

C. Porta, L. Mutti, and G. Tassi, Negative results of an Italian Group for 1148

(. G. Mesothelioma, Me.) pilot study of single-agent imatinib mesylate in malignant pleural 1149 mesothelioma, Cancer Chemother Pharmacol, vol.59, issue.1, pp.149-150, 2007.

B. A. Whitson and R. A. Kratzke, Molecular pathways in malignant pleural 1151 mesothelioma, Cancer Lett, vol.239, issue.2, pp.183-189, 2006.

M. C. Jaurand, J. Fleury-feith, and . Cells,

, Textbook of pleural diseases, pp.27-37, 2008.

C. D. Hoang, X. Zhang, and P. D. Scott, Selective activation of insulin receptor 1155 substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant 1156 phenotypes, Cancer Res, vol.64, issue.20, pp.7479-7485, 2004.

T. C. Lee, Y. Zhang, and C. Aston, Normal human mesothelial cells and 1158 mesothelioma cell lines express insulin-like growth factor I and associated molecules

. Res, , vol.53, pp.2858-2864, 1993.

Z. Liu and J. Klominek, Regulation of matrix metalloprotease activity in malignant 1161 mesothelioma cell lines by growth factors, Thorax, vol.58, issue.3, pp.198-203, 2003.

K. Kawaguchi, H. Murakami, and T. Taniguchi, Combined inhibition of MET 1163 and EGFR suppresses proliferation of malignant mesothelioma cells, Carcinogenesis, vol.1164, issue.7, pp.1097-1105, 2009.

R. Jagadeeswaran, P. C. Ma, and T. Y. Seiwert, , p.1166

, Met/hepatocyte growth factor pathway in malignant pleural mesothelioma, Cancer Res, vol.1167, issue.1, pp.352-361, 2006.

E. Tolnay, C. Kuhnen, T. Wiethege, J. E. Konig, B. Voss et al., Hepatocyte 1169 growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an 1170 increased microvessel density in malignant pleural mesothelioma, J Cancer Res Clin Oncol, vol.1171, issue.6, pp.291-296, 1998.

I. Thirkettle, P. Harvey, P. S. Hasleton, R. Y. Ball, and R. M. Warn, Immunoreactivity for 1173 cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas, Histopathology, vol.36, issue.6, pp.522-528, 1174.

P. Harvey, A. Warn, and S. Dobbin, Expression of HGF/SF in mesothelioma 1176 cell lines and its effects on cell motility, proliferation and morphology, Br J Cancer, vol.1177, issue.7, pp.1052-1059, 1998.

T. Mukohara, G. Civiello, and I. J. Davis, Inhibition of the met receptor in 1179 mesothelioma, Clin Cancer Res, vol.11, issue.22, pp.8122-8130, 2005.

M. De-melo, M. W. Gerbase, J. Curran, and J. C. Pache, Phosphorylated extracellular 1181 signal-regulated kinases are significantly increased in malignant mesothelioma, J Histochem, p.1182

, Cytochem, vol.54, issue.8, pp.855-861, 2006.

L. Vintman, S. Nielsen, A. Berner, R. Reich, and B. Davidson, Mitogen-activated 1184 protein kinase expression and activation does not differentiate benign from malignant 1185 mesothelial cells, Cancer, vol.103, issue.11, pp.2427-2433, 2005.

R. Eguchi, Y. Fujimori, and H. Takeda, Arsenic trioxide induces apoptosis 1187 through JNK and ERK in human mesothelioma cells, J Cell Physiol, vol.226, issue.3, pp.762-768, 2011.

W. B. Ou, C. Hubert, and J. M. Corson, Targeted inhibition of multiple receptor Page 52

M. Roth, J. Zhong, M. Tamm, and J. Szilard, Mesothelioma cells escape heat stress 1191 by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases, J Biomed, p.1192

, Biotechnol, p.451084, 2009.

A. Besson, S. M. Robbins, and V. W. Yong, PTEN/MMAC1/TEP1 in signal 1194 transduction and tumorigenesis, Eur J Biochem, vol.263, issue.3, pp.605-611, 1999.

J. Daubriac, J. Fleury-feith, and L. Kheuang, Malignant pleural mesothelioma 1196 cells resist anoikis as quiescent pluricellular aggregates. Cell Death and Differentiation, vol.16, pp.1146-1155, 1197.

D. A. Altomare, H. You, and G. H. Xiao, Human and mouse mesotheliomas 1199 exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor 1200 cell growth, Oncogene, vol.24, issue.40, pp.6080-6089, 2005.

Y. Suzuki, H. Murakami, and K. Kawaguchi, Activation of the PI3K-AKT 1202 pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, issue.2, pp.181-188, 1203.

I. Opitz, A. Soltermann, and M. Abaecherli, PTEN expression is a strong 1205 predictor of survival in mesothelioma patients, Eur J Cardiothorac Surg, vol.33, issue.3, pp.502-506, 2008.

H. Clevers, Wnt/beta-catenin signaling in development and disease, Cell, vol.127, issue.3, pp.469-480, 1207.

A. Y. Lee, B. He, and L. You, Dickkopf-1 antagonizes Wnt signaling 1209 independent of beta-catenin in human mesothelioma, Biochem Biophys Res Commun, vol.323, issue.4, pp.1246-1250, 1210.

J. Mazieres, L. You, and B. He, Wnt2 as a new therapeutic target in malignant 1212 pleural mesothelioma, Int J Cancer, vol.117, issue.2, pp.326-332, 2005.

Y. Kashiwakura, K. Ochiai, and M. Watanabe, Down-regulation of inhibition of 1214 differentiation-1 via activation of activating transcription factor 3 and Smad regulates

, REIC/Dickkopf-3-induced apoptosis, Cancer Res, vol.68, issue.20, pp.8333-8341, 2008.

T. Yokoyama, H. Osada, and H. Murakami, YAP1 is involved in mesothelioma 1217 development and negatively regulated by Merlin through phosphorylation, Carcinogenesis, vol.29, issue.11, pp.2139-2146, 1218.

H. Murakami, T. Mizuno, and T. Taniguchi, LATS2 Is a Tumor Suppressor

, Gene of Malignant Mesothelioma. Cancer Res, vol.71, issue.3, pp.873-883, 2011.

C. Thurneysen, I. Opitz, S. Kurtz, W. Weder, R. A. Stahel et al.,

, Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, vol.64, pp.140-147, 1223.

G. H. Xiao, R. Gallagher, and J. Shetler, The NF2 tumor suppressor gene product, p.1225

, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 1226 expression, Mol Cell Biol, vol.25, issue.6, pp.2384-2394, 2005.

P. I. Poulikakos, G. H. Xiao, R. Gallagher, S. Jablonski, S. C. Jhanwar et al., Re-1228 expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells 1229 and negatively regulates FAK, Oncogene, vol.25, issue.44, pp.5960-5968, 2006.

M. A. Lopez-lago, T. Okada, M. M. Murillo, N. Socci, and F. G. Giancotti, Loss of the 1231 tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent 1232 mTORC1 signaling, Mol Cell Biol, vol.29, issue.15, pp.4235-4249, 2009.

E. J. Song, S. H. Yim, E. Kim, N. S. Kim, and K. J. Lee, Human Fas-associated factor 1, 1234 interacting with ubiquitinated proteins and valosin-containing protein, is involved in the 1235 ubiquitin-proteasome pathway, Mol Cell Biol, vol.25, issue.6, pp.2511-2524, 2005.

D. A. Altomare, C. W. Menges, and P. J. , Activated TNF-alpha/NF-kappaB 1237 signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas 1238 from Arf knockout mice, Proc Natl Acad Sci, vol.106, issue.9, pp.3420-3425, 2009.

A. C. Borczuk, G. C. Cappellini, H. K. Kim, M. Hesdorffer, R. N. Taub et al.,

, Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome 1241 pathway as a therapeutic target in poor prognosis tumors, Oncogene, vol.26, issue.4, pp.610-617, 2007.

X. Sun, L. Wei, and J. Liden, Molecular characterization of tumour 1243 heterogeneity and malignant mesothelioma cell differentiation by gene profiling, J Pathol, vol.207, issue.1, pp.91-101, 1244.

A. Sartore-bianchi, F. Gasparri, and A. Galvani, Bortezomib inhibits nuclear 1246 factor-kappaB dependent survival and has potent in vivo activity in mesothelioma, p.1247

, Cancer Res, vol.13, pp.5942-5951, 2007.

X. Sun, M. Gulyas, A. Hjerpe, and K. Dobra, Proteasome inhibitor PSI induces 1249 apoptosis in human mesothelioma cells, Cancer Lett, vol.232, issue.2, pp.161-169, 2006.

B. Z. Yuan, J. A. Chapman, and S. H. Reynolds, Proteasome Inhibitor, vol.132, p.1251

, Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells

, Oncol, vol.1, issue.3, pp.129-140, 2008.

G. J. Gordon, M. Mani, and G. Maulik, Preclinical studies of the proteasome 1254 inhibitor bortezomib in malignant pleural mesothelioma, Cancer Chemother Pharmacol, vol.1255, issue.4, pp.549-558, 2008.

D. Barbone, T. M. Yang, J. R. Morgan, G. Gaudino, and C. Broaddus, Mammalian target 1257 of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma 1258 multicellular spheroids, J Biol Chem, vol.283, pp.13021-11330, 2008.

S. P. Frizelle, J. Grim, and J. Zhou, Re-expression of p16INK4a in mesothelioma 1260 cells results in cell cycle arrest, cell death, tumor suppression and tumor regression

, Oncogene, vol.16, issue.24, pp.3087-3095, 1998.

C. T. Yang, L. You, and C. C. Yeh, Adenovirus-mediated p14ARF gene transfer in 1263 human mesothelioma cells, J Natl Cancer Inst, vol.92, issue.8, pp.636-641, 2000.

C. T. Yang, L. You, K. Uematsu, C. C. Yeh, F. Mc-cormick et al., p14ARF 1265 modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53

, Cancer Res, vol.61, issue.16, pp.5959-5963, 2001.

K. W. Kim, R. W. Mutter, and C. D. Willey, Inhibition of survivin and aurora B 1268 kinase sensitizes mesothelioma cells by enhancing mitotic arrests, Int J Radiat Oncol Biol, p.1269

, Phys, vol.67, issue.5, pp.1519-1525, 2007.

J. Y. Kim, C. Harvard, and L. You, Stathmin is overexpressed in malignant 1271 mesothelioma, Anticancer Res, vol.27, issue.1A, pp.39-44, 2007.

Y. J. Wu, L. M. Parker, and N. E. Binder, The mesothelial keratins: a new family of 1273 cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia

, Cell, vol.31, issue.3, pp.693-703, 1982.

C. Vivo, C. Lecomte, and F. Levy, Cell cycle checkpoint status in human 1276 malignant mesothelioma cell lines: response to gamma radiation, Br J Cancer, vol.1277, issue.3, pp.388-395, 2003.

M. Bunderson-schelvan, A. K. Erbe, C. Schwanke, and M. A. Pershouse, Suppression 1279 of the mouse double minute 4 gene causes changes in cell cycle control in a human 1280 mesothelial cell line responsive to ultraviolet radiation exposure, Environ Mol Mutagen, vol.50, issue.9, pp.753-759, 1281.

B. W. Robinson, A. W. Musk, and R. A. Lake, Malignant mesothelioma, Lancet

L. Jin, V. J. Amatya, Y. Takeshima, L. Shrestha, K. Kushitani et al., Evaluation 1285 of apoptosis and immunohistochemical expression of the apoptosis-related proteins in 1286 mesothelioma, Hiroshima J Med Sci, vol.59, issue.2, pp.27-33, 2010.

Q. Lu, E. O. Harrington, and S. Rounds, Apoptosis and lung injury, Keio J Med, vol.54, issue.4, pp.184-189, 1288.

W. Liu, E. Bodle, J. Y. Chen, M. Gao, G. D. Rosen et al., Tumor necrosis 1290 factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in 1291 mesothelioma cell lines, Am J Respir Cell Mol Biol, vol.25, issue.1, pp.111-118, 2001.

M. R. Rippo, S. Moretti, and S. Vescovi, FLIP overexpression inhibits death 1293 receptor-induced apoptosis in malignant mesothelial cells, Oncogene, vol.23, issue.47, pp.7753-1294, 2004.

M. Tomasetti, M. R. Rippo, and R. Alleva, Alpha-tocopheryl succinate and 1296 TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma 1297 cells, Br J Cancer, vol.90, issue.8, pp.1644-1653, 2004.

K. S. Abayasiriwardana, D. Barbone, and K. U. Kim, Malignant mesothelioma 1299 cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim

, Mol Cancer Ther, vol.6, issue.10, pp.2766-2776, 2007.

M. H. Pespeni, M. Hodnett, and K. S. Abayasiriwardana, Sensitization of 1302 mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced 1303 apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt 1304 pathway, Cancer Res, vol.67, issue.6, pp.2865-2871, 2007.

S. I. Katz, L. Zhou, and G. Chao, Sorafenib inhibits ERK1/2 and MCL-1(L) 1306 phosphorylation levels resulting in caspase-independent cell death in malignant pleural 1307 mesothelioma, Cancer Biol Ther, vol.8, issue.24, pp.2406-2416, 2009.

S. M. Wilson, D. Barbone, and T. M. Yang, mTOR mediates survival signals in 1309 malignant mesothelioma grown as tumor fragment spheroids, Am J Respir Cell Mol Biol, vol.39, issue.5, pp.576-583, 1310.

Y. Soini, V. Kinnula, R. Kaarteenaho-wiik, E. Kurttila, K. Linnainmaa et al.,

, Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in 1313 malignant mesothelioma, Clin Cancer Res, vol.5, issue.11, pp.3508-3515, 1999.

W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao, Antisense therapy for 1315 malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product, J Thorac, p.1316

, Cardiovasc Surg, vol.123, issue.6, pp.1191-1198, 2002.

X. Cao, C. Rodarte, L. Zhang, C. D. Morgan, J. Littlejohn et al., Bcl2/bcl-1318 xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma, Cancer, vol.1319

, Biol Ther, vol.6, issue.2, pp.246-252, 2007.

J. E. Littlejohn, X. Cao, and S. D. Miller, Bcl-xL antisense oligonucleotide and 1321 cisplatin combination therapy extends survival in SCID mice with established mesothelioma 1322 xenografts, Int J Cancer, vol.123, issue.1, pp.202-208, 2008.

E. Varin, C. Denoyelle, and E. Brotin, Downregulation of Bcl-xL and Mcl-1 is 1324 sufficient to induce cell death in mesothelioma cells highly refractory to conventional 1325 chemotherapy, Carcinogenesis, vol.31, issue.6, pp.984-993, 2010.

S. L. O'kane, R. J. Pound, A. Campbell, N. Chaudhuri, M. J. Lind et al.,

, Expression of bcl-2 family members in malignant pleural mesothelioma, Acta Oncol, vol.45, issue.4, pp.449-453, 1328.

C. Xia, Z. Xu, and X. Yuan, Induction of apoptosis in mesothelioma cells by 1330 antisurvivin oligonucleotides, Mol Cancer Ther, vol.1, issue.9, pp.687-694, 2002.

N. Zaffaroni, A. Costa, and M. Pennati, Survivin is highly expressed and 1332 promotes cell survival in malignant peritoneal mesothelioma, Cell Oncol, vol.29, issue.6, pp.453-1333, 2007.

L. Kleinberg, A. K. Lie, V. A. Florenes, J. M. Nesland, and B. Davidson, Expression of 1335 inhibitor-of-apoptosis protein family members in malignant mesothelioma, Hum Pathol, vol.38, issue.7, pp.986-994, 1336.

J. Symanowski, N. Vogelzang, L. Zawel, P. Atadja, H. Pass et al., A histone 1338 deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely 1339 responsible for increased apoptosis with TRAIL, J Thorac Oncol, vol.4, issue.2, pp.149-160, 2009.

K. Dhaene, R. Hübner, S. Kumar-singh, B. Weyn, and E. Van-marck, Telomerase 1341 activity in human pleural mesothelioma, Thorax, vol.53, issue.11, pp.915-918, 1998.

R. Villa, M. G. Daidone, and R. Motta, Multiple mechanisms of telomere 1343 maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal 1344 mesothelioma, Clin Cancer Res, vol.14, issue.13, pp.4134-4140, 2008.

A. Catalano, M. Romano, I. Robuffo, L. Strizzi, and A. Procopio, Methionine 1346 aminopeptidase-2 regulates human mesothelioma cell survival. Role of Bcl-2 expression and 1347 telomerase activity, Am J Pathol, vol.159, issue.2, pp.721-731, 2001.

W. Amin, A. V. Parwani, and L. Schmandt, National Mesothelioma Virtual 1349 Bank: a standard based biospecimen and clinical data resource to enhance translational 1350 research, BMC Cancer, vol.8, p.236, 2008.